BibTex RIS Kaynak Göster
Yıl 2018, Cilt: 35 Sayı: 1, 55 - 60, 01.01.2018

Öz

Kaynakça

  • 1. Wehrum MJ, Buhimschi IA, Salafia C, Thung S, Bahtiyar MO, Werner EF, et al. Accreta complicating complete placenta previa is characterized by reduced systemic levels of vascular endothelial growth factor and by epithelial-to-mesenchymal transition of the invasive trophoblast. Am J Obstet Gynecol 2011;204:411.e1-411.e11.
  • 2. Hull AD, Moore TR. Multiple repeat cesareans and the threat of placenta accreta: incidence, diagnosis, management. Clin Perinatol 2011;38:285- 96.
  • 3. Demir R, Kaufmann P, Castellucci M, Erbengi T, Kotowski A. Fetal vasculogenesis and angiogenesis in human placental villi. Acta Anat (Basel) 1989;136:190-203.
  • 4. Dimitriadis E, Nie G, Hannan NJ, Paiva P, Salamonsen LA. Local regulation of implantation at the human fetal-maternal interface. Int J Dev Biol 2010;54:313-22.
  • 5. Ferrara N, Gerber HP, Lecouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.
  • 6. Ahmed A, Dunk C, Ahmad S, Khaliq A. Regulation of placental vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF) and soluble Flt-1 by oxygen--a review. Placenta 2000;21(Suppl A):16-24.
  • 7. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649-58.
  • 8. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672-83.
  • 9. Boufettal H, Feige JJ, Benharouga M, Aboussaouira T, Nadifi S, Mahdaoui S, et al. [Potential role of the angiogenic factor "EG-VEGF" in gestational trophoblastic diseases]. Pathol Biol (Paris) 2013;61:178-83.
  • 10. Semczuk-Sikora A, Krzyzanowski A, Stachowicz N, Robak J, Kraczkowski J, Kwiatek M, et al. [Maternal serum concentration of angiogenic factors: PIGF, VEGF and VEGFR-1 and placental volume in pregnancies complicated by intrauterine growth restriction]. Ginekol Pol 2007;78:783-6.
  • 11. Helske S, Vuorela P, Carpén O, Hornig C, Weich H, Halmesmäki E. Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies. Mol Hum Reprod 2001;7:205-10.
  • 12. Biberoglu E, Kirbas A, Daglar K, Biberoglu K, Timur H, Demirtas C, et al. Serum angiogenic profile in abnormal placentation. J Matern Fetal Neonatal Med 2016;29:3193-7.
  • 13. Pilloni E, Alemanno MG, Gaglioti P, Sciarrone A, Garofalo A, Biolcati M, et al. Accuracy of ultrasound in antenatal diagnosis of placental attachment disorders. Ultrasound Obstet Gynecol 2016;47:302-7.
  • 14. Li CM, Hou L, Zhang H, Zhang WY. CCL17 Induces Trophoblast Migration and Invasion by Regulating Matrix Metalloproteinase and Integrin Expression in Human First-Trimester Placenta. Reprod Sci 2014.
  • 15. Chaiworapongsa T, Romero R, Whitten AE, Korzeniewski SJ, Chaemsaithong P, Hernandez-Andrade E, et al. The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia. J Matern Fetal Neonatal Med 2016;29:1214-28.
  • 16. Borbely AU, Sandri S, Fernandes IR, Prado KM, Cardoso EC, Correa-Silva S, et al. The term basal plate of the human placenta as a source of functional extravillous trophoblast cells. Reprod Biol Endocrinol 2014;12:7.
  • 17. Tseng JJ, Chou MM, Hsieh YT, Wen MC, Ho ES, Hsu SL. Differential expression of vascular endothelial growth factor, placenta growth factor and their receptors in placentae from pregnancies complicated by placenta accreta. Placenta 2006;27:70-8.
  • 18. Charnock-Jones DS. Soluble flt-1 and the angiopoietins in the development and regulation of placental vasculature. J Anat 2002;200:607-15.
  • 19. McMahon K, Karumanchi SA, Stillman IE, Cummings P, Patton D, Easterling T. Does soluble fms-like tyrosine kinase-1 regulate placental invasion? Insight from the invasive placenta. Am J Obstet Gynecol 2014;210:68.e1-4.

Serum Angiogenic and Anti-angiogenic Markers in Pregnant Women with Placenta Percreta

Yıl 2018, Cilt: 35 Sayı: 1, 55 - 60, 01.01.2018

Öz

Background: Placenta percreta is the morbidly adherent form of all the placental invasion abnormalities. The pathology that underlies placenta percreta is poorly understood.Aims: To compare the levels of circulating vascular endothelial growth factor, placental growth factor and soluble fms-like tyrosine kinase 1 in pregnant women with placenta percreta to a control group.Study Design: Case-control study.Methods: Twenty-two women who underwent caesarean section due to placenta percreta and 22 women who underwent caesarean section for other obstetric reasons were included in this study. The diagnosis of placenta percreta was defined as extreme trophoblastic invasion involving serosa of the uterus. Venous blood samples were collected for biochemical comparison of circulating vascular endothelial growth factor, placental growth factor and soluble fms-like tyrosine kinase 1 from all pregnant women.Results: Women with placenta percreta were significantly older, had higher gravidity, received more frequent antenatal steroids and blood transfusions and delivered at an earlier gestational age when compared to the control group. In women with placenta percreta, preoperative circulating levels of vascular endothelial growth factor, placental growth factor and soluble fms-like tyrosine kinase 1 were lower than the controls (p<0.001, p<0.001 and p<0.05, respectively). While the postoperative levels of vascular endothelial growth factorand soluble fms-like tyrosine kinase 1 levels were higher in placenta percreta (p=0.001 and p<0.001, respectively), placental growth factor levels were similar in both groups.Conclusion: The findings of this study suggest that a decrease in vascular endothelial growth factor, placental growth factor and soluble fms-like tyrosine kinase 1 levels may be related to placenta percreta etiopathogenesis.

Kaynakça

  • 1. Wehrum MJ, Buhimschi IA, Salafia C, Thung S, Bahtiyar MO, Werner EF, et al. Accreta complicating complete placenta previa is characterized by reduced systemic levels of vascular endothelial growth factor and by epithelial-to-mesenchymal transition of the invasive trophoblast. Am J Obstet Gynecol 2011;204:411.e1-411.e11.
  • 2. Hull AD, Moore TR. Multiple repeat cesareans and the threat of placenta accreta: incidence, diagnosis, management. Clin Perinatol 2011;38:285- 96.
  • 3. Demir R, Kaufmann P, Castellucci M, Erbengi T, Kotowski A. Fetal vasculogenesis and angiogenesis in human placental villi. Acta Anat (Basel) 1989;136:190-203.
  • 4. Dimitriadis E, Nie G, Hannan NJ, Paiva P, Salamonsen LA. Local regulation of implantation at the human fetal-maternal interface. Int J Dev Biol 2010;54:313-22.
  • 5. Ferrara N, Gerber HP, Lecouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.
  • 6. Ahmed A, Dunk C, Ahmad S, Khaliq A. Regulation of placental vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF) and soluble Flt-1 by oxygen--a review. Placenta 2000;21(Suppl A):16-24.
  • 7. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649-58.
  • 8. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672-83.
  • 9. Boufettal H, Feige JJ, Benharouga M, Aboussaouira T, Nadifi S, Mahdaoui S, et al. [Potential role of the angiogenic factor "EG-VEGF" in gestational trophoblastic diseases]. Pathol Biol (Paris) 2013;61:178-83.
  • 10. Semczuk-Sikora A, Krzyzanowski A, Stachowicz N, Robak J, Kraczkowski J, Kwiatek M, et al. [Maternal serum concentration of angiogenic factors: PIGF, VEGF and VEGFR-1 and placental volume in pregnancies complicated by intrauterine growth restriction]. Ginekol Pol 2007;78:783-6.
  • 11. Helske S, Vuorela P, Carpén O, Hornig C, Weich H, Halmesmäki E. Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies. Mol Hum Reprod 2001;7:205-10.
  • 12. Biberoglu E, Kirbas A, Daglar K, Biberoglu K, Timur H, Demirtas C, et al. Serum angiogenic profile in abnormal placentation. J Matern Fetal Neonatal Med 2016;29:3193-7.
  • 13. Pilloni E, Alemanno MG, Gaglioti P, Sciarrone A, Garofalo A, Biolcati M, et al. Accuracy of ultrasound in antenatal diagnosis of placental attachment disorders. Ultrasound Obstet Gynecol 2016;47:302-7.
  • 14. Li CM, Hou L, Zhang H, Zhang WY. CCL17 Induces Trophoblast Migration and Invasion by Regulating Matrix Metalloproteinase and Integrin Expression in Human First-Trimester Placenta. Reprod Sci 2014.
  • 15. Chaiworapongsa T, Romero R, Whitten AE, Korzeniewski SJ, Chaemsaithong P, Hernandez-Andrade E, et al. The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia. J Matern Fetal Neonatal Med 2016;29:1214-28.
  • 16. Borbely AU, Sandri S, Fernandes IR, Prado KM, Cardoso EC, Correa-Silva S, et al. The term basal plate of the human placenta as a source of functional extravillous trophoblast cells. Reprod Biol Endocrinol 2014;12:7.
  • 17. Tseng JJ, Chou MM, Hsieh YT, Wen MC, Ho ES, Hsu SL. Differential expression of vascular endothelial growth factor, placenta growth factor and their receptors in placentae from pregnancies complicated by placenta accreta. Placenta 2006;27:70-8.
  • 18. Charnock-Jones DS. Soluble flt-1 and the angiopoietins in the development and regulation of placental vasculature. J Anat 2002;200:607-15.
  • 19. McMahon K, Karumanchi SA, Stillman IE, Cummings P, Patton D, Easterling T. Does soluble fms-like tyrosine kinase-1 regulate placental invasion? Insight from the invasive placenta. Am J Obstet Gynecol 2014;210:68.e1-4.
Toplam 19 adet kaynakça vardır.

Ayrıntılar

Diğer ID JA59UE25FD
Bölüm Araştırma Makalesi
Yazarlar

Hacer Uyanıkoğlu Bu kişi benim

Adnan İncebıyık Bu kişi benim

Ahmet B. Turp Bu kişi benim

Güler Çakmak Bu kişi benim

Sibel Sak Bu kişi benim

Neşe G. Hilali Bu kişi benim

Yayımlanma Tarihi 1 Ocak 2018
Yayımlandığı Sayı Yıl 2018 Cilt: 35 Sayı: 1

Kaynak Göster

APA Uyanıkoğlu, H., İncebıyık, A., Turp, A. B., Çakmak, G., vd. (2018). Serum Angiogenic and Anti-angiogenic Markers in Pregnant Women with Placenta Percreta. Balkan Medical Journal, 35(1), 55-60.
AMA Uyanıkoğlu H, İncebıyık A, Turp AB, Çakmak G, Sak S, Hilali NG. Serum Angiogenic and Anti-angiogenic Markers in Pregnant Women with Placenta Percreta. Balkan Medical Journal. Ocak 2018;35(1):55-60.
Chicago Uyanıkoğlu, Hacer, Adnan İncebıyık, Ahmet B. Turp, Güler Çakmak, Sibel Sak, ve Neşe G. Hilali. “Serum Angiogenic and Anti-Angiogenic Markers in Pregnant Women With Placenta Percreta”. Balkan Medical Journal 35, sy. 1 (Ocak 2018): 55-60.
EndNote Uyanıkoğlu H, İncebıyık A, Turp AB, Çakmak G, Sak S, Hilali NG (01 Ocak 2018) Serum Angiogenic and Anti-angiogenic Markers in Pregnant Women with Placenta Percreta. Balkan Medical Journal 35 1 55–60.
IEEE H. Uyanıkoğlu, A. İncebıyık, A. B. Turp, G. Çakmak, S. Sak, ve N. G. Hilali, “Serum Angiogenic and Anti-angiogenic Markers in Pregnant Women with Placenta Percreta”, Balkan Medical Journal, c. 35, sy. 1, ss. 55–60, 2018.
ISNAD Uyanıkoğlu, Hacer vd. “Serum Angiogenic and Anti-Angiogenic Markers in Pregnant Women With Placenta Percreta”. Balkan Medical Journal 35/1 (Ocak 2018), 55-60.
JAMA Uyanıkoğlu H, İncebıyık A, Turp AB, Çakmak G, Sak S, Hilali NG. Serum Angiogenic and Anti-angiogenic Markers in Pregnant Women with Placenta Percreta. Balkan Medical Journal. 2018;35:55–60.
MLA Uyanıkoğlu, Hacer vd. “Serum Angiogenic and Anti-Angiogenic Markers in Pregnant Women With Placenta Percreta”. Balkan Medical Journal, c. 35, sy. 1, 2018, ss. 55-60.
Vancouver Uyanıkoğlu H, İncebıyık A, Turp AB, Çakmak G, Sak S, Hilali NG. Serum Angiogenic and Anti-angiogenic Markers in Pregnant Women with Placenta Percreta. Balkan Medical Journal. 2018;35(1):55-60.